This JACC commentary discussed the risk-treatment paradox in chronic kidney disease, where patients at highest cardiovascular risk are least likely to receive evidence-based therapies including SGLT2 inhibitors and statins.
Publication date: 24 February 2026Source: JACC, Volume 87, Issue 7
